Abstract
AIM: To investigate feasibility, morbidity and surgical mortality of a docetaxel-based chemotherapy regimen randomly administered before or after gastrectomy in patients suffering from locally-advanced resectable gastric cancer. METHODS: Patients suffering from locally-advanced (T3-4 any N M0 or any T N1-3 M0) gastric carcinoma, staged with endoscopic ultrasound, bone scan, computed tomography, and laparoscopy, were assigned to receive four 21 d/cycles of TCF (docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, and fluorouracil 300 mg/m2 per day for days 1-14), either before (Arm A) or after (Arm B) gastrectomy. Operative morbidity, overall mortality, and severe adverse events were compared by intention-to-treat analysis. RESULTS: From November 1999 to November 2005, 70 patients were treated. After preoperative TCF (Arm A), thirty-two (94%) resections were performed, 85% of which were R0. Pathological response was complete in 4 patients (11.7%), and partial in 18 (55%). No surgical mortality and 28.5% morbidity rate were observed, similar to those of immediate surgery arm (P = 0.86). Serious chemotherapy adverse events tended to be more frequent in arm B (23% vs 11%, P = 0.07), with a single death per arm. CONCLUSION: Surgery following docetaxel-based chemotherapy was safe and with similar morbidity to immediate surgery in patients with locally-advanced resectable gastric carcinoma.
| Original language | English |
|---|---|
| Pages (from-to) | 868-874 |
| Number of pages | 7 |
| Journal | World Journal of Gastroenterology |
| Volume | 16 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Feb 21 2010 |
Fingerprint
Keywords
- Docetaxel
- Endoscopic ultrasonography
- Gastric cancer
- Laparoscopy
- Morbidity
- Neoadjuvant chemotherapy
ASJC Scopus subject areas
- Gastroenterology
Cite this
Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. / Biffi, Roberto; Fazio, Nicola; Luca, Fabrizio; Chiappa, Antonio; Andreoni, Bruno; Zampino, Maria Giulia; Roth, Arnaud; Schuller, Jan Christian; Fiori, Giancarla; Orsi, Franco; Bonomo, Guido; Crosta, Cristiano; Huber, Olivier.
In: World Journal of Gastroenterology, Vol. 16, No. 7, 21.02.2010, p. 868-874.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer
AU - Biffi, Roberto
AU - Fazio, Nicola
AU - Luca, Fabrizio
AU - Chiappa, Antonio
AU - Andreoni, Bruno
AU - Zampino, Maria Giulia
AU - Roth, Arnaud
AU - Schuller, Jan Christian
AU - Fiori, Giancarla
AU - Orsi, Franco
AU - Bonomo, Guido
AU - Crosta, Cristiano
AU - Huber, Olivier
PY - 2010/2/21
Y1 - 2010/2/21
N2 - AIM: To investigate feasibility, morbidity and surgical mortality of a docetaxel-based chemotherapy regimen randomly administered before or after gastrectomy in patients suffering from locally-advanced resectable gastric cancer. METHODS: Patients suffering from locally-advanced (T3-4 any N M0 or any T N1-3 M0) gastric carcinoma, staged with endoscopic ultrasound, bone scan, computed tomography, and laparoscopy, were assigned to receive four 21 d/cycles of TCF (docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, and fluorouracil 300 mg/m2 per day for days 1-14), either before (Arm A) or after (Arm B) gastrectomy. Operative morbidity, overall mortality, and severe adverse events were compared by intention-to-treat analysis. RESULTS: From November 1999 to November 2005, 70 patients were treated. After preoperative TCF (Arm A), thirty-two (94%) resections were performed, 85% of which were R0. Pathological response was complete in 4 patients (11.7%), and partial in 18 (55%). No surgical mortality and 28.5% morbidity rate were observed, similar to those of immediate surgery arm (P = 0.86). Serious chemotherapy adverse events tended to be more frequent in arm B (23% vs 11%, P = 0.07), with a single death per arm. CONCLUSION: Surgery following docetaxel-based chemotherapy was safe and with similar morbidity to immediate surgery in patients with locally-advanced resectable gastric carcinoma.
AB - AIM: To investigate feasibility, morbidity and surgical mortality of a docetaxel-based chemotherapy regimen randomly administered before or after gastrectomy in patients suffering from locally-advanced resectable gastric cancer. METHODS: Patients suffering from locally-advanced (T3-4 any N M0 or any T N1-3 M0) gastric carcinoma, staged with endoscopic ultrasound, bone scan, computed tomography, and laparoscopy, were assigned to receive four 21 d/cycles of TCF (docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, and fluorouracil 300 mg/m2 per day for days 1-14), either before (Arm A) or after (Arm B) gastrectomy. Operative morbidity, overall mortality, and severe adverse events were compared by intention-to-treat analysis. RESULTS: From November 1999 to November 2005, 70 patients were treated. After preoperative TCF (Arm A), thirty-two (94%) resections were performed, 85% of which were R0. Pathological response was complete in 4 patients (11.7%), and partial in 18 (55%). No surgical mortality and 28.5% morbidity rate were observed, similar to those of immediate surgery arm (P = 0.86). Serious chemotherapy adverse events tended to be more frequent in arm B (23% vs 11%, P = 0.07), with a single death per arm. CONCLUSION: Surgery following docetaxel-based chemotherapy was safe and with similar morbidity to immediate surgery in patients with locally-advanced resectable gastric carcinoma.
KW - Docetaxel
KW - Endoscopic ultrasonography
KW - Gastric cancer
KW - Laparoscopy
KW - Morbidity
KW - Neoadjuvant chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=77449092201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77449092201&partnerID=8YFLogxK
U2 - 10.3748/wjg.v16.i7.868
DO - 10.3748/wjg.v16.i7.868
M3 - Article
C2 - 20143466
AN - SCOPUS:77449092201
VL - 16
SP - 868
EP - 874
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
SN - 1007-9327
IS - 7
ER -